Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 | P30874 | 15/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.37 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22976573 | 1.00 | SSTR2 (0.47) | SSTR2KCNH2SSTR5SMPD3SYK | |
| SCHEMBL29653459 | 0.88 | SYK (0.47) | SSTR2KCNH2SYK | |
| SCHEMBL16694607 | 0.81 | SSTR2 (0.46) | SSTR2KCNH2SYK | |
| SCHEMBL22976824 | 0.81 | SSTR2 (0.72) | SSTR2KCNH2SMPD3 | |
| SCHEMBL22976828 | 0.81 | SSTR2 (0.72) | SSTR2KCNH2SMPD3 | |
| SCHEMBL21248811 | 0.80 | SMPD3 (0.35) | SMPD3FFAR4 | |
| SCHEMBL21248810 | 0.80 | SMPD3 (0.35) | SMPD3FFAR4 | |
| SCHEMBL28777519 | 0.80 | SSTR2 (0.48) | SSTR2KCNH2SSTR5FFAR4 | |
| SCHEMBL28777517 | 0.80 | SSTR2 (0.48) | SSTR2KCNH2SSTR5FFAR4 | |
| SCHEMBL16694764 | 0.78 | SSTR2 (0.57) | SSTR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4013748-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
| WO-2021030262-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | SSTR2 4/4885KCNH2 3581/4885SSTR5 1/4885 |
| US-20210047287-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | SSTR2 4/4885KCNH2 3581/4885SSTR5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.